Kos Inhaled Insulin Comparable To Lantus In Phase IIa Trial, Firm Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Kos' inhaled insulin formulation demonstrated equivalent efficacy and safety compared to Aventis' injectable basal insulin analog Lantus in a Phase IIa study, the firm reported Aug. 26
You may also be interested in...
Kos’ Niaspan/Simvastatin Combination NDA Planned For 2006
Two pivotal trials for the extended-release niacin/simvastatin fixed-dose combination are underway, Kos says. Firm expects the new combo to be superior to predecessor Advicor in lowering LDL-cholesterol and similar in raising HDL-C.
Kos’ Niaspan/Simvastatin Combination NDA Planned For 2006
Two pivotal trials for the extended-release niacin/simvastatin fixed-dose combination are underway, Kos says. Firm expects the new combo to be superior to predecessor Advicor in lowering LDL-cholesterol and similar in raising HDL-C.
Lilly/Alkermes Inhaled Insulin To Enter Late-Stage Development
The companies are finalizing plans for Phase II and Phase III trials following successful Phase II study in type 1 diabetes and completion of manufacturing scale-up and inhaler device development. The partnership is Lilly’s third stab at non-injectable insulin development.